ROYAL OAK—OncoCell MDx Inc., a startup incubated at Harvard University to develop sophisticated cancer diagnosis from a simple blood sample, has raised $22.2 million in a Preferred Series B funding round. The financing was led by San Francisco-based Savitr Capital LLC, with participation from existing investors. OncoCell began operations in 2013, and since then has
ANN ARBOR - Genomenon, Inc., and Shanghai Shanyi Biological Technology Co., Ltd have formed a partnership to provide Genomenon’s leading Mastermind Genomic Search Engine to clinical laboratory customers in China. Genomenon’s Mastermind is a genomic search engine wiith nearly 3,500 users in over 100 countries, becoming the search engine of choice when researching patient variants
FARMINGTON HILLS—Ocuphire Pharma Inc., a clinical-stage pharmaceutical company developing therapies to treat patients with a variety of ophthalmic disorders, announced that it has closed on over $5 million of financing. Investors include Jackson-based RBI Opportunities Fund, Douglas, Mich.-based Belle Capital Fund, Grand Rapids-based Grand Angels Fund, Farmington Hills-based First Capital Fund, Ann Arbor-based Michigan Angel
ROYAL OAK — OncoCell MDx has hired Kirk Wojno, M.D., as its chief medical officer. OncoCell MDx is developing new, noninvasive molecular diagnostic assays. Wojno, a renowned urologic pathologist and expert in prostate biopsy interpretation, joins an expanding, experienced executive team. OncoCell MDx also recently announced the appointments of Mark McDonough as president and CEO
BOSTON - There is no doubt that 3D bioprinting is a technology of the future. Imagine being able to print a kidney or liver on demand. This is a stark contrast to the long wait for a donor organ today. Currently, the average wait time for a liver is 4 to 5 months and 2.5
ROCHESTER—OptimizeRx Corp. (Nasdaq: OPRX), the Rochester-based provider of digital communication services for pharmaceutical companies to patients and healthcare providers, has announced a proposed underwritten public offering of shares of its common stock. The company sold 1,538,500 shares of its common stock at a price of $13 per share. The proceeds of the offering, before deducting
ROYAL OAK - Tember Shea, Portfolio Manager for Invest Detroit Ventures, interviews Mike Klein, CEO of Genomenon, to discuss the latest news coming out of the Ann Arbor-based gene therapy company. Mike Klein To listen, click on https://soundcloud.com/mike-brennan-841872555/e170-genomenon
TROY – A group of Michigan doctors is hosting an all-day forum June 8 in an effort to bridge the conversational gap between healthcare providers, patients and the cannabis industry to provide evidence supporting cannabis’ medical efficacy. “For those interested in gaining knowledge and resources regarding the medical benefits of cannabis, it will be extremely
ANN ARBOR—Genomenon Inc., the Ann Arbor-based genomics research information provider, has announced a partnership with Google to make the company’s genomic mutation data available on Google Cloud platform. Genomenon’s Cited Variants Reference (CVR) data will be a public dataset available in BigQuery, Google Cloud’s big data and machine learning data warehouse, for use in genomic applications. The
ROCHESTER—OptimizeRx Corp., the digital health messaging provider for the pharmaceutical industry, announced its latest platform integration with the health care industry’s leading acute electronic health record (EHR) systems, including Epic and Cerner. This latest announcement is a reflection of the company’s continued investment in hospitals and health systems, also emphasized in the latest company hiring
